What Changed in the DIR Fee Calculation After POS Reform
The Inflation Reduction Act's point-of-sale DIR reform was supposed to end retroactive DIR fees — the practice of PBMs clawing back reimbursement from pharmacies months after dispensing, based on performance metrics the pharmacy couldn't fully see or control at the time of fill. The reform took effect January 1, 2024. Retroactive DIR fees, as a line item, largely disappeared. What replaced them is more subtle, more permanent, and for many independent pharmacies, financially equivalent.
PBMs responded to POS reform by restructuring their performance tier systems. Performance metrics — medication adherence rates, star rating contributions, generic dispensing rates, patient satisfaction scores — were already part of the DIR calculation under the old system. Under the new system, they are the primary mechanism by which PBMs establish reimbursement rates at adjudication. A pharmacy in the top performance tier receives the highest reimbursement rate. A pharmacy in a lower performance tier receives a reduced rate — applied at the point of sale, in real time, on every claim. The fee is no longer retroactive. The reimbursement reduction is functionally identical.
The framing of "DIR reform" created an expectation that the financial pressure would ease. For pharmacies in the top performance tier with strong metric scores, it did — the elimination of retroactive uncertainty was real and meaningful. For pharmacies in the bottom two tiers of most PBM performance networks, the effective reimbursement rates in 2024 and 2025 have closely tracked or exceeded the DIR exposure they carried under the old retroactive system. The math changed. The pressure didn't.
The mechanism shift matters operationally. Under the retroactive system, pharmacies had a window between dispensing and reconciliation to understand their exposure. Under the new system, low-performance-tier pharmacies receive reduced reimbursement on every claim, in real time, from the moment their tier placement takes effect at the start of each plan year. There is no reconciliation period to identify the problem. There is no dispute window to contest the retroactive amount. There is only the tier placement — determined months earlier, based on metrics from the prior year — and the reimbursement rate it produces on every prescription fill going forward.
The recalibration required is straightforward but often hasn't happened: independent pharmacies need to understand their tier placement with each PBM, the specific metrics that determine it, and the reimbursement rate differential between their current tier and the top tier. That differential, applied across their annual claim volume, is the revenue opportunity that performance improvement represents. Most pharmacies have not done this calculation. That's the gap.
Two immediate priorities. First, contact your PBM representatives and request your current performance tier status for every PBM in your network. You are entitled to this information under most network agreements. Many pharmacies have never asked for it. Your tier placement determines your reimbursement rate on every claim in your network; not knowing it is not a neutral position. Second, pull your dispensing data and calculate your PDC rates for diabetes, hypertension, and cholesterol — the three medication adherence measures that most directly drive star ratings and PBM tier placement. If your rates are below 80% in any of these categories, you have a specific, addressable performance gap that is costing you real money at the point of adjudication on every affected claim. That is where your improvement effort should start.
Which Dispensing Categories Carry the Highest Exposure This Cycle
DIR fee exposure under the old retroactive system was concentrated in specialty pharmacy dispensing — high-cost biologics, limited distribution drugs, specialty injectables where margins were thin and retroactive clawbacks were disproportionately damaging. The transition to performance-tier-based reimbursement has broadened the exposure profile significantly. Categories that independent pharmacies historically treated as low-complexity, steady-margin dispensing are now directly implicated in the performance calculations that determine reimbursement rates across their entire book of business.
The expansion happened incrementally, without fanfare. PBMs added new metric categories to their performance scorecards over 2024 and 2025 as the POS reform framework settled. Pharmacies that reviewed their scorecard structure in early 2024 and assumed it was stable were operating on outdated information by mid-2025. The scorecard you need to review is the current one — not the one from the transition period.
Four dispensing categories now carry meaningful DIR-equivalent exposure for general independent pharmacy dispensing portfolios. The first is specialty-adjacent generics. As branded specialty medications come off-patent, their generic equivalents are crossing into performance tier calculations even though they are dispensed through standard pharmacy benefit channels. A pharmacy filling high volumes of certain biosimilar generics or specialty-adjacent generics may find those fills reflected in performance metrics that affect their overall tier placement — an interaction that did not exist two years ago.
The second is vaccine dispensing rates. Several major PBMs have incorporated vaccine administration rates into their performance scorecards for pharmacy networks. A pharmacy that administers vaccines to eligible patients at a rate below the network average may see that metric reflected negatively in their performance tier. This is new, it affects virtually all independent pharmacies, and most have not identified it as a DIR-equivalent exposure.
The third is medication adherence metrics — PDC rates for diabetes medications (specifically oral agents and insulins), antihypertensives, and statins. These are not new metrics. What has changed is the tier calculation weighting. PBMs increased the weighting of adherence metrics in their performance scoring as part of their response to CMS star rating pressure. A pharmacy whose PDC rates fall below network averages in these categories is now exposed to larger tier-to-tier reimbursement differentials than they carried under the pre-reform DIR structure.
The fourth category is the one most independent pharmacy owners have not yet encountered: statin use in persons with cardiovascular disease, and renin-angiotensin system antagonist prescribing rates. These metrics — borrowed from the CMS Part D star rating system — are being incorporated into PBM performance scorecards as PBMs align their quality frameworks with CMS quality standards. They measure whether eligible patients in your dispensing population are receiving the medications they should be on, based on their diagnosis codes. Pharmacies that proactively engage with prescribers on these metrics — identifying gaps and facilitating appropriate fills — score better. Pharmacies that passively dispense what is prescribed without clinical engagement score on whatever their patient population's adherence happens to be.
Pull your current performance scorecard from each PBM in your network. If you don't have the most recent version, request it in writing from your PBM network representative this week. Compare the metric categories on the current scorecard to what you have been tracking internally. Any metric on the scorecard that you are not actively monitoring is a blind spot in your performance management. The goal for September is to identify all blind spots before the Q4 performance measurement window closes and tier placements for 2027 begin to be determined.
The Audit Documentation That Protects Your Margins
Independent pharmacies facing PBM audits in the post-POS-reform environment are encountering a documentation environment that has shifted from the pre-reform period. The retroactive DIR clawback audit focused primarily on the accuracy of the data used to calculate the retroactive fee — medication adherence records, claim submission accuracy, patient eligibility verification. The performance-tier audit focuses on whether the metrics used to determine your tier placement were calculated correctly, and whether the reimbursement rate applied to your claims accurately reflects your tier status.
These are different audits with different documentation requirements. Pharmacies that prepared for the first type of audit — the retroactive data verification audit — are not necessarily prepared for the second type. And the stakes of the performance-tier audit are higher in one specific way: a finding that your tier placement was incorrect can generate a retroactive reimbursement adjustment going back to the date the incorrect tier took effect. That is the retroactive mechanism that POS reform was supposed to eliminate — re-emerging through the performance tier correction process.
Three documentation practices protect your margins in the current audit environment. The first is PDC rate documentation by medication class, maintained on a rolling basis rather than assembled reactively when an audit request arrives. Your PDC rates for diabetes, hypertension, and cholesterol medications should be calculated monthly, documented in your pharmacy management system, and retained. When a PBM audits your performance tier placement and challenges your adherence metrics, your internally calculated PDC rates — showing the same data from a different calculation source — are your evidence that the PBM's numbers require scrutiny.
The second documentation practice is prior authorization tracking. Every PA submission and approval should be logged with submission date, approval date, medication, prescriber, and outcome. This documentation matters in two contexts: as evidence of clinical engagement that supports your performance tier argument, and as the foundation for a clawback exposure reduction argument when PA approvals are delayed by PBM processing time rather than clinical dispute. A PA submitted on Day 1 and approved on Day 21 created a 21-day gap in which the patient may not have received their medication — a gap that affects your adherence metrics but is attributable to PBM processing delay, not to your dispensing practices. Documented PA timelines are the evidence that supports a metric dispute in that scenario.
The third documentation practice addresses generic dispensing and DAW code accuracy. Dispensed as written (DAW) codes govern whether a claim is classified as a generic fill or a brand fill. DAW-0 indicates no brand required by prescriber or patient — the pharmacy may dispense generic. DAW-1 indicates the prescriber required brand. The critical audit exposure: DAW-1 codes that are applied incorrectly — either because the prescriber's intent was unclear or because staff defaulted to DAW-1 to simplify the dispensing decision — inflate a pharmacy's brand fill rate and directly damage their generic dispensing rate metric. PBMs audit DAW coding patterns, and a pharmacy with an anomalously high DAW-1 rate relative to network averages is an audit target. Monthly DAW code review — pulling claims with DAW-1 codes and verifying that each one has documented prescriber brand authorization — is the practice that prevents the audit finding before it occurs.
The most powerful single action an independent pharmacy can take with respect to performance tier management is one that most pharmacies have never taken: requesting their performance scorecard from each PBM on a quarterly basis. You are entitled to it. The PBM is required to provide it under most network agreements. Most pharmacies have never asked, and as a result, they learn their tier placement when the new plan year begins — after the measurement period is over and tier placement is fixed. Requesting the scorecard quarterly gives you performance data while the measurement period is still open, while there is still time to improve metrics that are trending below tier thresholds.
The ask is simple. Contact your PBM network representative in writing. State that you are requesting your pharmacy's current performance scorecard under your network participation agreement. Request it for every PBM in your network. Document the request and the response. If a PBM declines to provide it, that refusal is itself useful information — it tells you which PBM relationships carry the least transparency and deserve the most scrutiny in your contracting review.
Know the game. Pull the scorecard. Play the metrics you can control.